Better Therapeutics to Host Conference Call to Review Results from Pivotal Clinical Trial of BT-001 for Type 2 Diabetes

Author's Avatar
Jul 26, 2022

Better+Therapeutics%2C+Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced it will host a conference call and webcast on Thursday, July 28, 2022, at 8:30 a.m. ET to review the results from the pivotal clinical trial of BT-001 after 180 days of treatment for type 2 diabetes. Members of the Better Therapeutics management team will be joined by Marc Bonaca, MD, MPH, Professor of Medicine and Director of Vascular Research at University of Colorado.